Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-29 · accession 0001209191-24-000067 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | 2023-12-29 | CBIO | Goldberg Mark Alan | Dir | A - Grant | $2.36 | +5,827 | 20.2K | +40% | +$13.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-12-29 | A | A | 5,827 | $2.36 | 20,244 | D | — | — | (F1) These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750. |